γ-Carbolines: A novel class of cannabinoid agonists with high aqueous solubility and restricted CNS penetration

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 4, 2012, Pages 1619-1624

  Cheng, Yun Xing ^a   Pourashraf, Mehrnaz ^a   Luo, Xuehong ^a   Srivastava, Sanjay ^a   Walpole, Christopher ^a   Salois, Dominic ^a   St Onge, Stephane ^a   Payza, Kemal ^a   Lessard, Etienne ^a   Yu, Xiao Hong ^a   Tomaszewski, Mirosław J ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Cannabinoid; Carbolines; Chronic pain

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR AGONIST; GAMMA CARBOLINE DERIVATIVE;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; CENTRAL NERVOUS SYSTEM; CHRONIC PAIN; CONTROLLED STUDY; DRUG PENETRATION; DRUG POTENCY; DRUG SOLUBILITY; DRUG TOLERABILITY; INFLAMMATORY PAIN; NONHUMAN; PHYSICAL CHEMISTRY; PROCESS OPTIMIZATION; RAT;

RATTUS;

EID: 84856651530     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.12.124     Document Type: Article

References (26)

1. Pertwee, R. G. Pharmacol. Ther. 1997, 74, 129.
2. Howlett, A. C.; Barth, F.; Bonner, T. I.; Cabral, G.; Casellas, P.; Devane, W. A.; Felder, C. C.; Herkenham, M.; Mackie, K.; Martin, B. R.; Mechoulam, R.; Pertwee, R. G. Pharmacol. Rev. 2002, 54, 161.
3. Buckley, N. E.; McCoy, K. L.; Mezey, E.; Bonner, T.; Zimmer, A.; Felder, C. C.; Glass, M.; Zimmer, A. Eur. J. Pharmacol. 2000, 396, 141.
4. Cabral, G. A.; Raborn, E. S.; Griffin, L.; Dennis, J.; Marciano-Cabral, F. Br. J. Pharmacol. 2009, 153, 240.
5. Chapman, V.; Finn, D. P. Rev. Anal. 2003, 7, 25.
6. Walter, L.; Stella, N. Br. J. Pharmacol. 2004, 141, 775.
7. Cheng, Y.; Hitchcock, S. A. Expert Opin. Investig. Drugs 2007, 16, 951.
8. Berman, J. S.; Symonds, C.; Birth, R. Pain 2004, 112, 299.
9. Wissel, J.; Haydn, T.; Muller, J.; Brenneis, C.; Berger, T.; Poewe, W.; Schelosky, L. D. J. Neurol. 2006, 253, 1337.
10. Burns, T. L.; Ineck, J. R. Ann. Pharmacother. 2006, 40, 251.
11. Agarwal, N.; Pacher, P.; Tegeder, I.; Amaya, F.; Constantin, C. E.; Brenner, G. J.; Rubino, T.; Michalski, C. W.; Marsicano, G.; Monory, K.; Mackie, K.; Marian, C.; Batkai, S.; Parolaro, D.; Fischer, M. J.; Reeh, P.; Kunos, G.; Kress, M.; Lutz, B.; Woolf, C. J.; Kuner, R. Nat. Neurosci. 2007, 10, 870.
12. Burstein, S. H.; Karst, M.; Schneider, U.; Zurier, R. B. Life Sci. 2004, 75, 1513.
13. Walker, J. M.; Hohmann, A. G. In Cannabinoids-Handbook of Experimental Pharmacology; Pertwee, R., Ed.; Springer: Berlin, 2005; p 509.
14. Pertwee, R. G. Br. J. Pharmacol. 2009, 156, 397.
15. Karst, M.; Wippermann, S. Expert Opin. Investig. Drugs 2009, 18, 125.
16. Kunos, G.; Osei-Hyiaman, D.; Batkai, S.; Sharkey, K. A.; Makriyannis, A. Trends Pharmacol. Sci. 2008, 10, 1.
17. Salim, K.; Schneider, U.; Burstein, S.; Hoy, L.; Karst, M. Neuropharmacology 2005, 48, 1164.
18. Dyson, A.; Peacock, M.; Chen, A.; Courade, J. P.; Yaqoob, M.; Groarke, A.; Brain, C.; Loong, Y.; Fox, A. Pain 2005, 116, 129.
19. Dziadulewicz, E. K.; Bevan, S. J.; Brain, C. T.; Coote, P. R.; Culshaw, A. J.; Davis, A. J.; Edwards, L. J.; Fisher, A. J.; Fox, A. J.; Gentry, C.; Groarke, A.; Hart, T. W.; Huber, W.; James, I. F.; Kesingland, A.; La Vecchia, L.; Loong, Y.; Lyothier, I.; McNair, K.; O'Farrell, C.; Peacock, M.; Portmann, R.; Schopfer, U.; Yaqoob, M.; Zadrobilek, J. J. Med. Chem. 2007, 50, 3851.
20. Yu, X. H.; Cao, C. Q.; Martino, G.; Puma, C.; Morinville, A.; St-Onge, S.; Lessard, E.; Perkins, M. N.; Laird, J. M. A. Pain 2010, 151, 337.
21. Thakur, G. A.; Tichkule, R.; Bajaj, S.; Makriyannis, A. Expert Opin. Ther. Patents 2009, 19, 1647.
22. Page, D.; Balaux, E.; Boisvert, L.; Liu, Z.; Milburn, C.; Tremblay, M.; Wei, Z.; Woo, S.; Luo, X.; Cheng, Y.-X.; Yang, H.; Srivastava, S.; Zhou, F.; Brown, W.; Tomaszewski, M.; Walpole, C.; Hodzic, L.; St-Onge, S.; Godbout, C.; Salois, D.; Payza, K. Bioorg. Med. Chem. Lett. 2008, 18, 3695.
23. Mahar Doan, K. M.; Humpreys, J. E.; Webster, L. O.; Wring, S. A.; Shamprine, L. J.; Serabit-Singh, C. J.; Adkinson, K. K.; Polli, J. W. J. Pharmacol. Exp. Ther. 2002, 303, 1029.
24. For recent reviews on strategies to mitigate hERG activity, see (a) Jamieson, C.; Moir, E. M.; Rankovic, Z.; Wishart, G. J. Med. Chem. 2006, 49, 5029
25. (b) Durdagi, S.; Subbotina, J.; Lees-Miller, J.; Guo, J.; Duff, H. J.; Noskov, S. Y. Curr. Med. Chem. 2010, 17, 3514.
26. Brain samples were corrected for 2% blood contamination according to Heisey SR. Brain and choroid plexus blood volumes in vertebrates. Comp. Biochem. Physiol. 1968, Aug; 26(2):489.